Sathya Prathipati is a Senior Partner at McKinsey & Company’s Mumbai office in India.

Sathya works with clients across industries, with a focus on pharmaceuticals and consumer goods.

Sathya leads McKinsey’s Pharmaceuticals Generics Practice globally and leads our Pharmaceutical and Healthcare Practice in India. He is the co-convener of the seminal Global Pharmaceuticals Generics industry CEO conference.

Sathya works with his clients on themes spanning performance improvement transformations, corporate strategy and technology enablement across China, India, Western Europe and the Americas.

Sathya has been a speaker at the Harvard Business School on Changing Landscape of Indian Healthcare, the International Generics CEO conference (Munich) on the future of the global Pharmaceutical Generics industry, as a key note at the Google-McKinsey digital health summit in India, the Asia Generics conference (Singapore) and a panelist on several conferences on topics spanning the global Generics industry, healthcare in India and the Indian consumer. He is the coauthor of the CII-McKinsey publication on ‘Healthcare 3.0’, the FICCI–McKinsey report on the Indian Lifesciences industry and several globally disseminated whitepapers on the pharmaceutical generics industry.

Examples of his recent client service include:

1. Developing the technology strategy roadmap for a top 3 consumer goods player in India
2. Developing the 5-year corporate strategy for an European generics company
3. Doubling margins of a business unit through a multi-faceted operations turnaround at a large Indian pharmaceutical company
4. Accelerating frontline sales growth for a leading Indian hospital chain and large Indian generic manufacturer
5. Leading the post-merger effort of two multi-billion dollar organizations to integrate their business functions and capture over $ 500 Mn of synergies
6. Leading the diligence of a US-based consumer asset as a strategic investment for an Indian conglomerate
7. Led the development and launch of a first of its kind technology platforms that achieved 80% adoption in the entire target population within the first week of launch

Prior to joining McKinsey, Sathya interned with the Technology, Media and Telecommunications desk of the Investment Banking Division (IBD) at Goldman Sachs & Co. in London.

Sathya received a Post Graduate Diploma in Management from the Indian Institute of Management-Bangalore (IIMB) and is a mechanical engineer by qualification

Saumil is the Country Head and General Manager for Novartis Oncology and heads business operations for India, Srilanka, Nepal and Maldives. Along with this, he has additional responsibility as Head of Marketing and Commercial Excellence for Asia Cluster. He is a member of Country Leadership Team of Novartis in India.

Saumil has 25 years of experience in pharma industry, spearheading businesses growth for leading organizations in the industry. He has been a part of leadership teams for almost a decade. With his rich experience, Saumil specializes in navigating growth strategies in complex healthcare markets through commercial effectiveness and effective stakeholder management.

Before joining Novartis, Saumil worked with Esai Pharmaceuticals, one of the leading Japanese pharmaceutical companies, as the Senior Vice President for Commercial Operations. He was associated with Roche for more than 11 years and was responsible for strategising and developing the Oncology business of Roche India; Frost & Sullivan awarded Roche India, the Best Oncology Company for three consecutive years, under his leadership. Prior to this, Saumil was associated with Johnson & Johnson and Eli Lilly and company, in managerial roles.

Saumil holds a Master’s degree in Business Administration and Marketing Management from Symbiosis Institute of Management Studies. He has completed his Bachelor’s degree in Pharmaceutical Sciences from K.M. Kundnani college of Pharmacy

Mr. S. Sridhar, Managing Director of Pfizer Limited, is leading Pfizer Inc’s commercial business in India having market capitalisation of US $ 2.7 billion. He is a member of the Pfizer Inc. Global Blueprint Leaders Forum and the Pfizer Asia Emerging Market Leadership Team.

Sridhar’s current responsibility pans across Pfizer’s off patent and innovative portfolio. He has in his career successfully steered many strategic projects, global brand launches, business restructuring actions, Mergers & Acquisitions, Joint Ventures, Pricing & Access initiatives. Sridhar is a strong people’s man and leads the Colleague engagement/ Culture work stream for Pfizer India.

Sridhar is a Chartered Accountant with 27 years of experience. He has successfully donned multiple hats in his career as Chief Financial Officer, Business Unit and Supply Chain Head and now the Managing Director of Pfizer India business since March 2016.

Sridhar is an Executive Member of Organisation of Pharmaceutical Producers of India (an association of Research Based Organisations) and is also the Chair of its Finance and Taxation Work Group. He is also the Chair of The Federation of Indian Chambers of Commerce and Industry (FICCI) Pharma Committee.

Prior to joining Pfizer, Sridhar spent 13 years with Diageo, the world’s largest alcoholic beverages company. He was the Finance Director when he left Diageo India.

Outside of office, Sridhar loves to cook and spend time in his second home in a tribal belt in the outskirts of Mumbai.

Umang Vohra has been Managing Director and Global Chief Executive Officer (MD & GCEO) of Cipla since September 2016. Umang joined Cipla in October 2015 as its Global Chief Financial Officer, and from January 2016 to August 2016 was Cipla’s Global Chief Operating Officer.
After gaining degrees in engineering, marketing and finance, Umang was associated with companies such as Eicher Motors and PepsiCo. Prior to joining Cipla, Umang was Head of the North America business for Dr. Reddy’s Laboratories. Through his previous roles in India and the USA, he has built a distinguished career spanning almost two decades with deep understanding and experience in various aspects of the global pharmaceutical business.

Under Umang’s leadership, Cipla has built strong momentum in its home markets, augmented its capability, strengthened its core, and shown significant improvement in its operating margin and profitability. At the helm of the Management Council of Cipla, Umang’s big-picture agenda is to define and execute Cipla’s strategic growth roadmap and geographical footprint, identify the next levers of growth, invest in innovation for the future, and build the right organisation. Recognised as an action-oriented industry leader, Umang is a firm believer in the power of agile business models, disruptive technologies, data-driven analytics and a future-ready workforce with a view to shaping the healthcare ecosystem and making a difference to the lives of patients.

Dr Vikas Gupta as head of Cipla India prescription business which makes up the biggest chunk of domestic sales. Vikas has over 20 years of experience in different therapies and business transformation interventions across various geographies
Vikas’ expertise includes delivery of profitable and sustainable top line by driving teams, innovative sales & marketing plans and creating mega brands.

In his earlier stint he used to lead the Acute Therapy business for Cipla and has led business roles across therapy areas including chronic, metabolic disorders and respiratory portfolio at Glenmark and Ranbaxy for India and international markets.